Prem S Shah
CIK 1900910 · View on SEC EDGAR ↗
Insider
First SEC filing: Jan. 10, 2022 · Latest: April 2, 2026
On this page
- Insider at Companies where this person is a reporting insider.
- Insider transactions Every share this person bought or sold, from Form 4 filings.
- Derivatives Options and other derivative holdings reported by this person.
- Initial holdings The stakes this person held when they first started reporting.
- Compensation Executive pay disclosed in company proxy statements.
Insider at
Insider transactions
0 buys (P)
0 sells (S)
Net:
$0
+ 42 non-open-market transactions below
last 12 months, based on the transactions shown below
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
42 other filings hidden
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| Feb. 16, 2024 | CVS | S | 29,473 | $76.95 | $2,267,947 | 39,765 Direct | -42.57% | Disposed | 22.2% (price as of 2026-08-20) |
| April 8, 2022 | CVS | S 10b5-1 | 3,130 | $105.00 | $328,650 | 43,453 Direct | -6.72% | Disposed | -10.4% (price as of 2026-08-20) |
| April 8, 2022 | CVS | S 10b5-1 | 4,103 | $105.00 | $430,815 | 46,583 Direct | -8.09% | Disposed | -10.4% (price as of 2026-08-20) |
| April 8, 2022 | CVS | S 10b5-1 | 5,719 | $105.00 | $600,495 | 46,583 Direct | -10.93% | Disposed | -10.4% (price as of 2026-08-20) |
| April 8, 2022 | CVS | S 10b5-1 | 3,157 | $105.00 | $331,485 | 46,583 Direct | -6.35% | Disposed | -10.4% (price as of 2026-08-20) |
| April 8, 2022 | CVS | S 10b5-1 | 845 | $105.00 | $88,725 | 46,583 Direct | -1.78% | Disposed | -10.4% (price as of 2026-08-20) |
| March 30, 2022 | CVS | S 10b5-1 | 5,346 | $104.70 | $559,726 | 59,071 Direct | -8.30% | Disposed | -10.2% (price as of 2026-08-20) |
| March 17, 2022 | CVS | S | 2,935 | $106.65 | $313,018 | 59,071 Direct | -4.73% | Disposed | -11.8% (price as of 2026-08-20) |
| March 17, 2022 | CVS | S | 1,689 | $106.65 | $180,132 | 59,071 Direct | -2.78% | Disposed | -11.8% (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 31, 2026 | CVS | Stock Option [F3] | Common Stock (161,676) | $71.82 | March 31, 2036 | 161,676 | Acquired |
| April 1, 2025 | CVS | Stock Option [F3] | Common Stock (112,289) | $67.98 | April 1, 2035 | 112,289 | Acquired |
| March 17, 2025 | CVS | Stock Option [F1] | Common Stock (846) | $62.21 | April 1, 2025 | 846 | Disposed |
| Nov. 30, 2024 | CVS | Premium Stock Option [F12] | Common Stock (746,268) | $71.82 | Nov. 30, 2031 | 746,268 | Acquired |
| April 1, 2024 | CVS | Stock Option | Common Stock (62,695) | $79.56 | April 1, 2034 | 62,695 | Acquired |
| April 1, 2023 | CVS | Stock Option [F12] | Common Stock (89,073) | $74.31 | April 1, 2033 | 89,073 | Acquired |
| April 8, 2022 | CVS | Stock Option [F8] | Common Stock (4,103) | $74.30 | April 1, 2031 | 4,103 | Disposed |
| April 8, 2022 | CVS | Stock Option [F7] | Common Stock (5,719) | $58.34 | April 1, 2030 | 5,719 | Disposed |
| April 8, 2022 | CVS | Stock Option [F6] | Common Stock (3,157) | $54.19 | April 1, 2029 | 3,157 | Disposed |
| April 8, 2022 | CVS | Stock Option [F5] | Common Stock (845) | $62.21 | April 1, 2025 | 845 | Disposed |
| April 1, 2022 | CVS | Stock Option | Common Stock (41,580) | $101.09 | April 1, 2032 | 41,580 | Acquired |
| March 30, 2022 | CVS | Stock Option [F10] | Common Stock (5,346) | $102.26 | April 1, 2022 | 5,346 | Disposed |
| March 17, 2022 | CVS | Stock Option [F9] | Common Stock (2,935) | $104.82 | April 1, 2023 | 2,935 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 17 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Jan. 10, 2022 | CVS | Common Stock | 11,980 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F1] | 575 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F2] | 2,884 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F3] | 15,427 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F4] | 1,808 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F5] | 1,925 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F6] | 6,393 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F7] | 4,373 | Direct |
| Jan. 10, 2022 | CVS | Common Stock (restricted) [F8] | 2,798 | Direct |
| Jan. 10, 2022 | CVS | Stock Unit (deferred) [F9] | 5,625 | Direct |
| Jan. 10, 2022 | CVS | Stock Option [F10]→ Common Stock (5,870) | 5,870 | Direct |
| Jan. 10, 2022 | CVS | Stock Option [F11]→ Common Stock (5,346) | 5,346 | Direct |
| Jan. 10, 2022 | CVS | Stock Option [F12]→ Common Stock (1,691) | 1,691 | Direct |
| Jan. 10, 2022 | CVS | Stock Option [F13]→ Common Stock (12,626) | 12,626 | Direct |
| Jan. 10, 2022 | CVS | Stock Option [F14]→ Common Stock (34,315) | 34,315 | Direct |
| Jan. 10, 2022 | CVS | Stock Option [F15]→ Common Stock (32,826) | 32,826 | Direct |
| Jan. 10, 2022 | CVS | Stock Option [F16]→ Common Stock (26,580) | 26,580 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
CVS
President and Group President| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2025 | $1,100,000 | — | — | — | $3,013,000 | — | $266,297 | $13,379,210 |
| 2024 | $972,917 | — | — | — | $0 | — | $293,113 | $13,265,855 |
| 2023 | $950,000 | — | $4,499,937 | $1,499,989 | $1,421,000 | — | $211,440 | $8,582,366 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.